Maresa Altomonte
Siena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Journal: The Lancet. Respiratory medicine
Published: September 09, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 29, 2020
Challenges in lung cancer therapy during the COVID-19 pandemic.
Journal: The Lancet. Respiratory medicine
Published: April 02, 2020
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Journal: Expert opinion on biological therapy
Published: August 01, 2018
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: January 11, 2018
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13-15, 2016.
Journal: Cancer immunology, immunotherapy : CII
Published: July 05, 2017
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 06, 2017
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.
Journal: Oncoimmunology
Published: February 03, 2017
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 22, 2015
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: January 14, 2015
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Journal: Journal of translational medicine
Published: March 24, 2014
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: September 17, 2013
Last Updated: 09/26/2026